BCL11A gene DNA methylation contributes to the risk of type 2 diabetes in males

Experimental and Therapeutic Medicine

Volumn 8, Issue 2, 2014, Pages 459-463

  Tang, Linlin ^a   Wang, Lingyan ^b   Ye, Huadan ^a   Xu, Xuting ^a   Hong, Qingxiao ^a   Wang, Hongwei ^c   Xu, Leiting ^a,b   Bu, Shizhong ^b   Zhang, Lina ^a,b   Cheng, Jia ^a   Liu, Panpan ^a   Ye, Meng ^a   Mai, Yifeng ^a   Duan, Shiwei ^a  

^a NINGBO UNIVERSITY   (China)

^b NINGBO NO 2 HOSPITAL   (China)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

BCL11A; CpG island; DNA methylation; Gender; Type 2 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; CHOLESTEROL; GLUCOSE; TRIACYLGLYCEROL; URIC ACID;

ADULT; ARTICLE; BCL11A GENE; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; FEMALE; GENDER; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; POLYMERASE CHAIN REACTION; PYROSEQUENCING; SEQUENCE ANALYSIS; SPECTROPHOTOMETRY;

EID: 84902598844     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.1783     Document Type: Article

References (42)

1. Afkarian M, Sachs MC, Kestenbaum B, et al: Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol 24: 302-308, 2013.
2. Papa G, Degano C, Iurato MP, Licciardello C, Maiorana R and Finocchiaro C: Macrovascular complication phenotypes in type 2 diabetic patients. Cardiovasc Diabetol 12: 20, 2013.
3. Ginter E and Simko V: Global prevalence and future of diabetes mellitus. Adv Exp Med Biol 771: 35-41, 2012.
4. Biasini E, Unterberger U, Solomon IH, et al: A mutant prion protein sensitizes neurons to glutamate-induced excitotoxicity. J Neurosci 33: 2408-2418, 2013.
5. Franks PW: Gene x environment interactions in type 2 diabetes. Curr Diab Rep 11: 552-561, 2011.
6. Wittmeier KD, Wicklow BA, Sellers EA, Griffith AT, Dean HJ and McGavock JM: Success with lifestyle monotherapy in youth with new-onset type 2 diabetes. Paediatr Child Health 17: 129-132, 2012.
7. Tobias DK, Hu FB, Chavarro J, Rosner B, Mozaffarian D and Zhang C: Healthful dietary patterns and type 2 diabetes mellitus risk among women with a history of gestational diabetes mellitus. Arch Intern Med 172: 1566-1572, 2012.
8. Tentolouris N, Andrianakos A, Karanikolas G, et al: Type 2 diabetes mellitus is associated with obesity, smoking and low socioeconomic status in large and representative samples of rural, urban, and suburban adult Greek populations. Hormones (Athens) 11: 458-467, 2012.
9. Drong AW, Lindgren CM and McCarthy MI: The genetic and epigenetic basis of type 2 diabetes and obesity. Clin Pharmacol Ther 92: 707-715, 2012.
10. Simmons RA: Programming of DNA methylation in type 2 diabetes. Diabetologia 56: 947-948, 2013.
11. Gilbert ER and Liu D: Epigenetics: the missing link to understanding β-cell dysfunction in the pathogenesis of type 2 diabetes. Epigenetics 7: 841-852, 2012.
12. Kirchner H, Osler ME, Krook A and Zierath JR: Epigenetic flexibility in metabolic regulation: disease cause and prevention? Trends Cell Biol 23: 203-209, 2013.
13. Zeng Y, Gu P, Liu K and Huang P: Maternal protein restriction in rats leads to reduced PGC-1α expression via altered DNA methylation in skeletal muscle. Mol Med Rep 7: 306-312, 2013.
14. Yang BT, Dayeh TA, Volkov PA, et al: Increased DNA methylation and decreased expression of PDX-1 in pancreatic islets from patients with type 2 diabetes. Mol Endocrinol 26: 1203-1212, 2012.
15. Liu ZH, Chen LL, Deng XL, et al: Methylation status of CpG sites in the MCP-1 promoter is correlated to serum MCP-1 in type 2 diabetes. J Endocrinol Invest 35: 585-589, 2012.
16. Yang M, Sun JZ, Sun YL, You W, Dai J and Li GS: Association between leptin gene promoter methylation and type 2 diabetes mellitus. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 29: 474-477, 2012 (In Chinese).
17. Burdge GC, Hoile SP and Lillycrop KA: Epigenetics: are there implications for personalised nutrition? Curr Opin Clin Nutr Metab Care 15: 442-447, 2012.
18. Yu Y, Wang J, Khaled W, et al: Bcl11a is essential for lymphoid development and negatively regulates p53. J Exp Med 209: 2467-2483, 2012.
19. Uda M, Galanello R, Sanna S, et al: Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia. Proc Natl Acad Sci USA 105: 1620-1625, 2008.
20. Ishii N, Wei M, Kakehashi A, et al: Enhanced urinary bladder, liver and colon carcinogenesis in zucker diabetic fatty rats in a multiorgan carcinogenesis bioassay: Evidence for mechanisms involving activation of PI3K signaling and impairment of p53 on urinary bladder carcinogenesis. J Toxicol Pathol 24: 25-36, 2011.
21. Labie D: BCL11A controls the expression of the human fetal hemoglobin. Med Sci (Paris) 28: 923-925, 2012 (In French).
22. Xu J, Bauer DE, Kerenyi MA, et al: Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A. Proc Natl Acad Sci USA 110: 6518-6523, 2013.
23. Pardini VC, Victória IM, Pieroni FB, et al: Fetal hemoglobin levels are related to metabolic control in diabetic subjects. Braz J Med Biol Res 32: 695-701, 1999.
24. Simonis-Bik AM, Nijpels G, van Haeften TW, et al: Gene variants in the novel type 2 diabetes loci CDC123/CAMK1D, THADA, ADAMTS9, BCL11A, and MTNR1B affect different aspects of pancreatic beta-cell function. Diabetes 59: 293-301, 2010.
25. Jonsson A, Ladenvall C, Ahluwalia TS, et al: Effects of common genetic variants associated with type 2 diabetes and glycemic traits on α-and β-cell function and insulin action in humans. Diabetes 62: 2978-2983, 2013.
26. Cauchi S, Ezzidi I, El Achhab Y, et al: European genetic variants associated with type 2 diabetes in North African Arabs. Diabetes Metab 38: 316-323, 2012.
27. Langberg KA, Ma L, Sharma NK, et al; American Diabetes Association GENNID Study Group: Single nucleotide polymorphisms in JAZF1 and BCL11A gene are nominally associated with type 2 diabetes in African-American families from the GENNID study. J Hum Genet 57: 57-61, 2012.
28. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. World Health Organization. Geneva, Switzerland p21, 2006.
29. Lolekha PH, Srisawasdi P, Jearanaikoon P, Wetprasit N, Sriwanthana B and Kroll MH: Performance of four sources of cholesterol oxidase for serum cholesterol determination by the enzymatic endpoint method. Clin Chim Acta 339: 135-145, 2004.
30. Schumann G, Klauke R, Canalias F, et al: IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 °C. Part 9: reference procedure for the measurement of catalytic concentration of alkaline phosphatase International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Scientific Division, Committee on Reference Systems of Enzymes (C-RSE) (1)). Clin Chem Lab Med 49: 1439-1446, 2011.
31. Guo JA, Mo PS and Li GX: Immobilization of glucose oxidase and peroxidase and their application in flow-injection analysis for glucose in serum. Appl Biochem Biotechnol 23: 15-24, 1990.
32. Jiang D, Zheng D, Wang L, et al: Elevated PLA2G7 gene promoter methylation as a gender-specific marker of aging increases the risk of coronary heart disease in females. PLoS One 8: e59752, 2013.
33. Harada H, Miyamoto K, Yamashita Y, et al: Methylation of breast cancer susceptibility gene 1 (BRCA1) predicts recurrence in patients with curatively resected stage I non-small cell lung cancer. Cancer 119: 792-798, 2013.
34. Cheng J, Wang L, Xu L, et al: Gender-dependent miR-375 promoter methylation and the risk of type 2 diabetes. Exp Ther Med 5: 1687-1692, 2013.
35. Legato MJ, Gelzer A, Goland R, et al; Writing Group for The Partnership for Gender-Specific Medicine: Gender-specific care of the patient with diabetes: review and recommendations. Gend Med 3: 131-158, 2006.
36. Huxley R, Barzi F and Woodward M: Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 332: 73-78, 2006.
37. Alzahrani SH, Hess K, Price JF, et al: Gender-specific alterations in fibrin structure function in type 2 diabetes: associations with cardiometabolic and vascular markers. J Clin Endocrinol Metab 97: E2282-E2287, 2012.
38. Dekker LH, Nicolaou M, van der A DL, et al: Sex differences in the association between serum ferritin and fasting glucose in type 2 diabetes among South Asian Surinamese, African Surinamese, and ethnic Dutch: the population-based SUNSET study. Diabetes Care 36: 965-971, 2013.
39. Burghardt KJ, Pilsner JR, Bly MJ and Ellingrod VL: DNA methylation in schizophrenia subjects: gender and MTHFR 677C/T genotype differences. Epigenomics 4: 261-268, 2012.
40. Zoppini G, Negri C, Stoico V, Casati S, Pichiri I and Bonora E: Triglyceride-high-density lipoprotein cholesterol is associated with microvascular complications in type 2 diabetes mellitus. Metabolism 61: 22-29, 2012.
41. Henderson SR, Maitland R, Mustafa OG, Miell J, Crook MA and Kottegoda SR: Severe hypertriglyceridaemia in type 2 diabetes mellitus: beneficial effect of continuous insulin infusion. QJM 106: 355-359, 2013.
42. Kulis M, Queiros AC, Beekman R and Martin-Subero JI: Intragenic DNA methylation in transcriptional regulation, normal differentiation and cancer. Biochim Biophys Acta 1829: 1161-1174, 2013.